Premium
A macrolide from Streptomyces sp. modulates apoptosis and autophagy through Mcl‐1 downregulation in human breast cancer cells
Author(s) -
Chiu ChangFang,
Chiu ShihJiuan,
Bai LiYuan,
Feng ChiaHsien,
Hu JingLan,
Lin WeiYu,
Huang HaoYu,
Weng JingRu
Publication year - 2021
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.23128
Subject(s) - autophagy , apoptosis , downregulation and upregulation , poly adp ribose polymerase , protein kinase b , blot , cancer research , mcf 7 , western blot , biology , cancer cell , cytotoxicity , cell growth , cancer , chemistry , biochemistry , human breast , in vitro , polymerase , dna , genetics , gene
Abstract Secondary metabolites in marine organisms exhibit various pharmacological activities against diseases, such as cancer. In this study, the anti‐proliferative effect of JBIR‐100, a macrolide isolated from Streptomyces sp., was investigated in breast cancer cells. Cell growth was inhibited in response to JBIR‐100 treatment concentration‐ and time‐dependently in both MCF‐7 and MDA‐MB‐231 breast cancer cells. JBIR‐100 caused apoptosis, as verified by caspase activation and the cleavage of PARP. Western blotting revealed that JBIR‐100 modulated the expression of Akt/NF‐κB signaling components and Bcl‐2 family members. Overexpression of Mcl‐1 partially rescued MCF‐7 cells from JBIR‐100‐induced cytotoxicity. In addition, transmission electron microscopy analyses, confocal analysis, and western blot assay indicated that JBIR‐100 inhibited autophagy in MCF‐7 cells. Exposure to the autophagy inhibitor did not synergize JBIR‐100‐induced apoptosis. In summary, our results suggested that JBIR‐100 may be potentially used for breast cancer therapy.